Don­ald Trump will leave the White House with­out any ma­jor drug pric­ing plan to his name.

A fed­er­al judge on Wednes­day agreed to is­sue a tem­po­rary re­strain­ing or­der against Trump’s con­tro­ver­sial “most fa­vored na­tion” plan, which Trump tried to push through in an ex­ec­u­tive or­der. The plan would have lim­it­ed Medicare re­im­burse­ments to what drug com­pa­nies are paid in oth­er af­flu­ent na­tions — which is cur­rent­ly far less than the pre­mi­ums avail­able in the US.

The plan had been pushed through the process in an at­tempt to make it ef­fec­tive New Year’s day. With the re­strain­ing or­der, how­ev­er, it’s un­like­ly to ever see the light of day.

PhRMA and a whole pha­lanx of in­dus­try groups like the AHA who sought the or­der were pre­pared to fight tooth and nail against the pro­pos­al. And come Jan­u­ary 20, all the play­ers will re­assess a de­bate that has run on for years as Joe Biden is sworn in.

The on­ly cer­tain thing about all this: The de­bate over drug pric­ing shows no sign of end­ing any­time soon.

Trump tried to get this to fly through an in­ter­im fi­nal rule, which would have cir­cum­vent­ed the usu­al dis­cus­sion pe­ri­od.

In a state­ment, PhRMA gen­er­al coun­sel James Stansel lam­bast­ed the pol­i­cy and the pro­ce­dure.

The Most Fa­vored Na­tion In­ter­im Fi­nal Rule is bad pol­i­cy that is con­trary to law and that the ad­min­is­tra­tion ex­press­ly ad­mits will dis­rupt pa­tients’ ac­cess to med­i­cines. By push­ing through a na­tion­wide, manda­to­ry pol­i­cy change, the ad­min­is­tra­tion is es­sen­tial­ly rewrit­ing the Medicare statute. It is cir­cum­vent­ing Con­gress en­tire­ly, ig­nor­ing the roles as­signed to the ex­ec­u­tive and leg­isla­tive branch­es.

Paul McKenzie took over as CEO of Australian pharma giant CSL this month, following in the footsteps of long-time CSL vet Paul Perreault.

With an eye on mRNA, and quickly commercializing its new, $3.5 million-per-shot gene therapy for hemophilia B, McKenzie and chief medical officer Bill Mezzanotte answered some questions from Endpoints News this afternoon about where McKenzie is going to take the company and what advances may be coming to market from CSL’s pipeline. Below is a lightly edited transcript.

Boehringer Ingelheim reported human pharma sales of €18.5 billion on Wednesday, led by type 2 diabetes and heart failure drug Jardiance and pulmonary fibrosis med Ofev. Jardiance sales reached €5.8 billion, growing 39% year over year, while Ofev took in €3.2 billion, notching its own 20.6% annual jump.

However, Boehringer is also looking ahead with its pipeline, estimating “In the next seven years the company expects about 20 regulatory approvals in human pharma.”

The FDA today approved Emergent BioSolutions’ Narcan brand naloxone nasal spray for over-the-counter sales. The nod was expected and comes on the heels of a unanimous 19-0 advisory committee vote in favor of approval last month.

The move to OTC means the opioid overdose reversal agent will now be available on grocery, convenience and gas stations shelves, as well as potentially for purchase online.